Vcreate
Vcreate is a biotechnology company that leverages machine learning and novel molecular biology to engineer human T-cell receptors (TCRs) for disease treatment. Their platform accelerates the discovery of TCR-based therapies by enabling the interrogation of millions of TCR-antigen interactions, representing a 100x speedup compared to existing methods. Vcreate's AI algorithms design TCRs to target intracellular disease-specific antigens, including rare cancer mutations, allowing for the development of highly precise drugs that can destroy target cells while sparing normal ones. The company is supported by institutions like Astellas, MBC Biolabs, and the National Institutes of Health.
Vcreate
Vcreate is a biotechnology company that leverages machine learning and novel molecular biology to engineer human T-cell receptors (TCRs) for disease treatment. Their platform accelerates the discovery of TCR-based therapies by enabling the interrogation of millions of TCR-antigen interactions, representing a 100x speedup compared to existing methods. Vcreate's AI algorithms design TCRs to target intracellular disease-specific antigens, including rare cancer mutations, allowing for the development of highly precise drugs that can destroy target cells while sparing normal ones. The company is supported by institutions like Astellas, MBC Biolabs, and the National Institutes of Health.